Special DNA Testing Offered in Response to Swine Influenza Epidemic

Personal genome company, BioResolve, Inc has introduced a DNA testing service that reveals an individual's innate resistance or vulnerabilities to infectious diseases, such as swine flu. The final report states an individual's ratio of surviving a worldwide pandemic with respect to the average human, and looks into all types of infectious diseases.

Ottawa, Canada, May 08, 2009 --(PR.com)-- BioResolve, a provider of genome-wide DNA testing so that individuals can make informed health decisions, is offering a detailed DNA test report with a free online calculator to individuals who are interested in knowing about their innate vulnerabilities or resistances to infectious diseases like swine flu.

Why some individuals resist infection or recover quickly, whereas others experience severe disease associated with infection is a fundamental question of primary concern when faced with the prospect of an infectious disease's epidemic - like the latest swine flu scare.

BioResolve suggests that one of the most significant actions that can be taken to reduce the spread of an epidemic is to identify the groups at risk so that they can take special precautions. This can include: staying at home, maintaining perfect hand hygiene, being alert to early symptoms and getting quick medical attention.

But to dive into deeper details, a DNA test may be required since it can accurately pin-point the specific risks factors that an individual may have. BioResolve does this by determining an individual's comparative survival ratio, which shows how an individual's risk to infectious diseases like influenza compares to the general public.

The ratio is found using a simple two-step process. The first step involves a questionnaire, freely available online to anyone, where an individual can privately provide the calculator with information such as their age, gender, country of residence and their medical history. This information is used to instantly calculate an individual's pandemic survival ratio.

The second step involves a DNA testing service that looks at key DNA site to evaluate an individual's general immune system quality, potential genetic complication determined by DNA, genetic predispositions to aggravating factors, as well as it's innate resistance or vulnerabilities to a wide range of infectious diseases including; influenza, malaria, HIV resistance, susceptibility to SARS, hepatitis, norovirus resistance, etc.

The result of this service is a complete profile description of an individual's resistance or vulnerabilities to a wide array of infectious diseases, with a special focus on influenza and the swine flu. The summary result is an individual's survival ratio. The test is designed so that the mean score is 100 and any deviation from this value indicates a higher risk of complications proportional to the magnitude of the deviation. A more in depth look at the report will pin-point the most significant factors so that an individual will know what to work on and what to avoid.

Alexandre Harvey-Tremblay, President of BioResolve, said, "One of the best thing that can be done is to identify groups of individuals that may be at an increased risk of developing severe complications from an infectious disease so that they can take better precautions. If someone has a clear understanding of his risks, he may decide to take extra precautions he may not have chosen to do had he not known about them."

About BioResolve, Inc.:
BioResolve, Inc. is a privately owned company operating in Ottawa, Canada. Founded by Alexandre Harvey-Tremblay, BioResolve's goal is to help individuals acquire the information they need to make more informed health decisions. BioResolve provides individuals with knowledge of their genetic predispositions to various diseases and then helps learn how to improve their health or to lessen the impact of these diseases. BioResolve is part of a growing industry of personalized medicine where treatments and diagnostics are provided relying on information specific to the DNA of the patient. For more information, visit www.bioresolve.com.

BioResolve, Inc.
Alexandre Harvey-Tremblay